About this Journal Submit a Manuscript Table of Contents
Journal of Obesity
Volume 2011 (2011), Article ID 765473, 7 pages
http://dx.doi.org/10.1155/2011/765473
Clinical Study

Influence of Sleeve Gastrectomy on NASH and Type 2 Diabetes Mellitus

1Department of General and Visceral Surgery, Albert-Ludwigs-University, Hugstetter Straße 55, 79106 Freiburg, Germany
2Department of Surgery, Champain de Chalons, 2 Rue Charles Simon, 51308 Vitry-le-France, Frankreich, France
3Department of Physiology, Silesian Medical University, Jordana 19, 41-800 Zabrze, Poland
4Department of Laparoscopic Surgery, International Medical Center, P.O. Box 2173, Jeddah 21451, Saudi Arabia

Received 31 August 2010; Accepted 26 October 2010

Academic Editor: Francesco Saverio Papadia

Copyright © 2011 W. K. Karcz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. T. Wang, R. L. Koretz, and H. F. Yee, “Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review,” American Journal of Medicine, vol. 115, no. 7, pp. 554–559, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. G. C. Farrell and C. Z. Larter, “Nonalcoholic fatty liver disease: from steatosis to cirrhosis,” Hepatology, vol. 43, no. 2, supplement 1, pp. S99–S112, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. Edmison and A. J. McCullough, “Pathogenesis of non-alcoholic steatohepatitis: human data,” Clinics in Liver Disease, vol. 11, no. 1, pp. 75–104, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. E. Bugianesi, N. Leone, and N. Leone, “Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma,” Gastroenterology, vol. 123, no. 1, pp. 134–140, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Torres and S. A. Harrison, “Diagnosis and therapy of nonalcoholic steatohepatitis,” Gastroenterology, vol. 134, no. 6, pp. 1682–1698, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. V. Ratziu, F. Charlotte, and F. Charlotte, “Sampling variability of liver biopsy in nonalcoholic fatty liver disease,” Gastroenterology, vol. 128, no. 7, pp. 1898–1906, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. R. Lewis and S. R. Mohanty, “Nonalcoholic fatty liver disease: a review and update,” Digestive Diseases and Sciences, vol. 55, no. 3, pp. 560–578, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. S. E. Wozniak, L. L. Gee, M. S. Wachtel, and E. E. Frezza, “Adipose tissue: the new endocrine organ? a review article,” Digestive Diseases and Sciences, vol. 54, no. 9, pp. 1847–1856, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. P. Després, R. Ross, G. Boka, N. Alméras, and I. Lemieux, “Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat the ADAGIO-lipids trial,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 3, pp. 416–423, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. G. P. Aithal, J. A. Thomas, and J. A. Thomas, “Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis,” Gastroenterology, vol. 135, no. 4, pp. 1176–1184, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. B. A. Neuschwander-Tetri, E. M. Brunt, K. R. Wehmeier, D. Oliver, and B. R. Bacon, “Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone,” Hepatology, vol. 38, no. 4, pp. 1008–1017, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. A. Uygun, A. Kadayifci, and A. Kadayifci, “Metformin in the treatment of patients with non-alcoholic steatohepatitis,” Alimentary Pharmacology and Therapeutics, vol. 19, no. 5, pp. 537–544, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Ekstedt, L. E. Franzén, U. L. Mathiesen, M. Holmqvist, G. Bodemar, and S. Kechagias, “Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study,” Journal of Hepatology, vol. 47, no. 1, pp. 135–141, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. P. Després, A. Golay, and L. Sjöström, “Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia,” New England Journal of Medicine, vol. 353, no. 20, pp. 2121–2134, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. P. Marceau, S. Biron, R. A. Bourque, M. Potvin, F. S. Hould, and S. Simard, “Biliopancreatic diversion with a new type of gastrectomy,” Obesity Surgery, vol. 3, no. 1, pp. 29–35, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. J. P. Regan, W. B. Inabnet, M. Gagner, and A. Pomp, “Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient,” Obesity Surgery, vol. 13, no. 6, pp. 861–864, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. S. M. Han, W. W. Kim, and JI. H. Oh, “Results of laparoscopic sleeve gastrectomy (LSG) at 1 year in morbidly obese Korean patients,” Obesity Surgery, vol. 15, no. 10, pp. 1469–1475, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. S. Kuesters, G. Marjanovic, and W. K. Karcz, “Redo operations after bariatric and metabolic surgery,” Zentralblatt fur Chirurgie, vol. 134, no. 1, pp. 50–56, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. W. J. Lee, K. H. Ser, and K. H. Ser, “Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion,” Surgery, vol. 147, no. 5, pp. 664–669, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. J. Vidal, A. Ibarzabal, F. Romero, S. Delgado, D. Momblán, L. Flores, and A. Lacy, “Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects,” Obesity Surgery, vol. 18, no. 9, pp. 1077–1082, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. D. Nocca, D. Krawczykowsky, and D. Krawczykowsky, “A prospective multicenter study of 163 sleeve gastrectomies: results at 1 and 2 years,” Obesity Surgery, vol. 18, no. 5, pp. 560–565, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. E. M. Brunt, C. G. Janney, A. M. Di Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon, “Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions,” American Journal of Gastroenterology, vol. 94, no. 9, pp. 2467–2474, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. N. Basso, et al., “Laparoscopic sleeve gastrectomy as first stage or definitive intent in 300 consecutive cases,” Surgical Endoscopy. In press.
  24. E. Menenakos, K. M. Stamou, K. Albanopoulos, J. Papailiou, D. Theodorou, and E. Leandros, “Laparoscopic sleeve gastrectomy performed with intent to treat morbid obesity: a prospective single-center study of 261 patients with a median follow-up of 1 year,” Obesity Surgery, vol. 20, no. 3, pp. 276–282, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. R. A. Weiner, S. Weiner, I. Pomhoff, C. Jacobi, W. Makarewicz, and G. Weigand, “Laparoscopic sleeve gastrectomy—influence of sleeve size and resected gastric volume,” Obesity Surgery, vol. 17, no. 10, pp. 1297–1305, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Caiazzo, L. Arnalsteen, and L. Arnalsteen, “Long-term metabolic outcome and quality of life after laparoscopic adjustable gastric banding in obese patients with type 2 diabetes mellitus or impaired fasting glucose,” British Journal of Surgery, vol. 97, no. 6, pp. 884–891, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. P. R. Schauer, B. Burguera, and B. Burguera, “Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus,” Annals of Surgery, vol. 238, no. 4, pp. 467–485, 2003. View at Scopus
  28. P. Mathurin, F. Gonzalez, and F. Gonzalez, “The evolution of severe steatosis after bariatric surgery is related to insulin resistance,” Gastroenterology, vol. 130, no. 6, pp. 1617–1624, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. R. Singhal, M. Kitchen, S. Bridgwater, and P. Super, “Metabolic outcomes of obese diabetic patients following laparoscopic adjustable gastric banding,” Obesity Surgery, vol. 18, no. 11, pp. 1400–1405, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. J. B. Dixon, P. S. Bhathal, and P. E. O'Brien, “Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement,” Obesity Surgery, vol. 16, no. 10, pp. 1278–1286, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. A. Ulitsky, A. N. Ananthakrishnan, and A. N. Ananthakrishnan, “A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients,” Obesity Surgery, vol. 20, no. 6, pp. 685–691, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. A. Ulitsky, A. N. Ananthakrishnan, and A. N. Ananthakrishnan, “A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients,” Obesity Surgery, vol. 20, no. 6, pp. 685–691, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. N. C. Chavez-Tapia, F. I. Tellez-Avila, T. Barrientos-Gutierrez, N. Mendez-Sanchez, J. Lizardi-Cervera, and M. Uribe, “Bariatric surgery for non-alcoholic steatohepatitis in obese patients,” Cochrane Database of Systematic Reviews, no. 1, p. CD007340, 2010. View at Scopus
  34. F. Abbatini, M. Rizzello, G. Casella, G. Alessandri, D. Capoccia, F. Leonetti, and N. Basso, “Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes,” Surgical Endoscopy, vol. 24, no. 5, pp. 1005–1010, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. R. Peterli, B. Wölnerhanssen, and B. Wölnerhanssen, “Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial,” Annals of Surgery, vol. 250, no. 2, pp. 234–241, 2009. View at Publisher · View at Google Scholar · View at PubMed
  36. S. Shah, P. Shah, J. Todkar, M. Gagner, S. Sonar, and S. Solav, “Prospective controlled study of effect of laparoscopic sleeve gastrectomy on small bowel transit time and gastric emptying half-time in morbidly obese patients with type 2 diabetes mellitus,” Surgery for Obesity and Related Diseases, vol. 6, no. 2, pp. 152–157, 2010. View at Publisher · View at Google Scholar · View at PubMed
  37. S. N. Karamanakos, K. Vagenas, F. Kalfarentzos, and T. K. Alexandrides, “Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study,” Annals of Surgery, vol. 247, no. 3, pp. 401–407, 2008.
  38. K. Meirelles, T. Ahmed, D. M. Culnan, C. J. Lynch, C. H. Lang, and R. N. Cooney, “Mechanisms of glucose homeostasis after roux-en-y gastric bypass surgery in the obese, insulin-resistant zucker rat,” Annals of Surgery, vol. 249, no. 2, pp. 277–285, 2009. View at Publisher · View at Google Scholar · View at PubMed
  39. X. Ding, N. K. Saxena, S. Lin, N. Gupta, and F. A. Anania, “Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice,” Hepatology, vol. 43, no. 1, pp. 173–181, 2006. View at Publisher · View at Google Scholar · View at PubMed
  40. M. E. Tushuizen, M. C. Bunck, P. J. Pouwels, J. H. T. van Waesberghe, M. Diamant, and R. J. Heine, “Incretin mimetics as a novel therapeutic option for hepatic steatosis,” Liver International, vol. 26, no. 8, pp. 1015–1017, 2006. View at Publisher · View at Google Scholar · View at PubMed
  41. G. Targher, L. Bertolini, S. Rodella, G. Zoppini, L. Scala, L. Zenari, and G. Falezza, “Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease,” Clinical Endocrinology, vol. 64, no. 6, pp. 679–683, 2006. View at Publisher · View at Google Scholar · View at PubMed
  42. A. Xu, Y. Wang, H. Keshaw, L. Y. Xu, K. S. L. Lam, and G. J. S. Cooper, “The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice,” Journal of Clinical Investigation, vol. 112, no. 1, pp. 91–100, 2003. View at Publisher · View at Google Scholar · View at PubMed
  43. D. Pessayre, B. Fromenty, and A. Mansouri, “Mitochondrial injury in steatohepatitis,” European Journal of Gastroenterology and Hepatology, vol. 16, no. 11, pp. 1095–1105, 2004. View at Publisher · View at Google Scholar